Stem Cell Isolation Devices and Technologies Market Globally Expected to Drive Growth through 2020

Stem cells are present in several areas of the body such as the bone marrow, adipose tissue and cord blood. Until recently embryonic stem cells and adult stem cells were the only two natural-state cells available for research and treatment. These cells have a remarkable potential of developing into a variety of other cells with a specific function. They operate as a repair and replacement system to replenish spent cells within the body. They are unspecialized cells capable of renewing themselves through cell division. In recent times, ongoing research has enabled scientists to artificially induce stem cells into becoming cells with specific functions. Due to low scalability, scientists had to look for other alternative sources of creating similar cells as well which led to the introduction of induced pluripotent stem cells or iPSCs.

Stem cell isolation has risen in the past several years due to research on scalability of stem cells and trend away from autologous stem cell treatment. BMT or bone marrow transplant was the first initiative that provided an allogenic treatment with stem cells as matching donors were searched for treating severe debilitating conditions. Current devices are majorly targeted for adipose derived stem cells. Conventional treatments focused on using mesenchymal stem cells that were isolated from bone marrow and other tissues including cord blood, peripheral blood, fallopian tube, fetal liver and lung. Autologous iliac crest bone graft continues to be the gold standard because it provides osteoprogenitor cells, an osteoconductive matrix, and osteoinductive molecules that are the three essential elements for bone formation.

Click For Full Report And TOC@ http://www.sa-brc.com/Global-Stem-Cell-Isolation-Devices-and-Technologies-Market-Assessment--Forecast-2016---2020/upcomingdetail35

The isolation and purification of stem cells along with therapeutic delivery requires specialized devices for accurate transplantation. This is due to the requisite for achieving high cellular retension for damage repair. This ongoing research focuses on the existing market and the upcoming devices for stem cell isolation from various tissues and delivery of stem cells through various modes such as trans-coronary, trans-endocardial and intracoronary delivery among other on-site delivery.

There are several companies operating in this highly competitive market. The top players include Cytori (Celution), Tissue Genesis (Incellator), Stempeutics (Stempeutron), Cellular Biomedicine Group (A-Stromal ProCeller), SynGen (SynGenX-1000), BioSafe (Sepax-2), PNC International (CHA-Station) and Neogenesis (UNiStation). Along with isolation devices, the market demand is also rising for support devices such as those for photo-activation prior to injecting stem cells. Currently adipose derived stem cells are getting the greatest attention primarily due to the relative ease of extraction and isolation using normal minimally invasive liposuction procedures.

For More Research Reports@ http://www.sa-brc.com/register.php

Stem cell therapy and isolation devices are gaining great demand in South-East Asia’s emerging economies such as Indonesia, Singapore, South Korea and Thailand. The regions are also known for their budding medical tourism market. Very soon hospitals in the regions are expected to offer breakthrough stem cell therapy for a fraction of the cost paid in developed countries. North America and Europe are currently the largest markets for stem cell isolation devices. However, being a naive market, Asia-Pacific is expected to catch up very quickly to international markets. China and Japan represent significant opportunities with several universities and research institutes developing better and more innovative technologies. Current ongoing research estimates peg the market for stem cell extraction and isolation devices to be approximately US$ 1.2 billion across the world and growing fast. With increasing applications and research in therapeutics, the demand from hospitals, cosmetic clinics and other office (out-patient) settings will soon be procuring licensed devices for expanding operations.

NOTE: This report is currently under research and will be made available to clients on request.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.